OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible

FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.